|
US5965362A
(en)
|
1992-03-04 |
1999-10-12 |
The Regents Of The University Of California |
Comparative genomic hybridization (CGH)
|
|
CZ292061B6
(cs)
|
1994-03-17 |
2003-07-16 |
Merck Patent Gmbh |
Jednořetězcové fragmenty protilátek a protilátky proti receptoru epidermálního růstového faktoru, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
|
|
WO2001060803A1
(en)
|
2000-02-15 |
2001-08-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused imidazolium derivatives
|
|
ES2398099T3
(es)
|
2001-02-19 |
2013-03-13 |
Merck Patent Gmbh |
Anticuerpos anti-EGFR modificados con inmunogenicidad reducida
|
|
NZ530212A
(en)
|
2001-06-13 |
2006-09-29 |
Genmab As |
An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR)
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
CN100343248C
(zh)
|
2003-04-15 |
2007-10-17 |
安斯泰来制药株式会社 |
溴化物及其晶体
|
|
PE20050928A1
(es)
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
|
CA2561516A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
WO2005111213A1
(ja)
|
2004-05-18 |
2005-11-24 |
Kurume University |
Ｍｙｃ標的遺伝子mimitin
|
|
WO2006036941A2
(en)
|
2004-09-27 |
2006-04-06 |
Kosan Biosciences Incorporated |
Specific kinase inhibitors
|
|
WO2007058823A2
(en)
|
2005-11-12 |
2007-05-24 |
Eli Lilly And Company |
Anti-egfr antibodies
|
|
WO2007086342A1
(ja)
|
2006-01-27 |
2007-08-02 |
National University Corporation Chiba University |
c-myc遺伝子転写抑制因子FIRのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
TWI398252B
(zh)
|
2006-05-26 |
2013-06-11 |
諾華公司 |
吡咯并嘧啶化合物及其用途
|
|
CA2661618A1
(en)
|
2006-08-25 |
2008-02-28 |
Astellas Pharma Inc. |
Stabilized pharmaceutical composition
|
|
MX2009004785A
(es)
|
2006-10-31 |
2009-06-05 |
Schering Corp |
Amidas 2-aminotiazol-4-carboxilicas como inhibidores de proteina quinasa.
|
|
US7618992B2
(en)
|
2006-12-29 |
2009-11-17 |
Astellas Pharma Inc. |
Method of treating cancer by co-administration of anticancer agents
|
|
CN101910167A
(zh)
|
2007-10-29 |
2010-12-08 |
先灵公司 |
噻唑甲酰胺衍生物及其治疗癌症
|
|
WO2009064675A1
(en)
|
2007-11-12 |
2009-05-22 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
WO2010056931A1
(en)
|
2008-11-14 |
2010-05-20 |
Intelligent Oncotherapeutics, Inc. |
Methods for identification of tumor phenotype and treatment
|
|
US8710068B2
(en)
|
2009-01-19 |
2014-04-29 |
The Trustees Of The University Of Pennsylvania |
Method of treating cancer using a survivin inhibitor
|
|
EP3028699B1
(en)
*
|
2010-02-25 |
2018-03-21 |
Dana-Farber Cancer Institute, Inc. |
Braf mutations conferring resistance to braf inhibitors
|
|
WO2011130232A1
(en)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
|
|
US8709419B2
(en)
*
|
2010-08-17 |
2014-04-29 |
Hoffmann-La Roche, Inc. |
Combination therapy
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
JP2014156400A
(ja)
|
2011-05-24 |
2014-08-28 |
Astellas Pharma Inc |
腫瘍の画像診断用標識誘導体
|
|
WO2012167099A1
(en)
|
2011-06-01 |
2012-12-06 |
Baylor College Of Medicine |
Biomarkers and therapy for cancer
|
|
FI20115876A0
(fi)
|
2011-09-06 |
2011-09-06 |
Turun Yliopisto |
Yhdistelmähoito
|
|
US20130122005A1
(en)
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
|
EP2780354A4
(en)
|
2011-11-16 |
2015-06-24 |
Oncomed Pharm Inc |
HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
|
|
US9662329B2
(en)
|
2012-03-26 |
2017-05-30 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of survivin antagonists in polyomavirus-related disease
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
SG10201907684PA
(en)
|
2013-01-15 |
2019-10-30 |
Aragon Pharmaceuticals Inc |
Androgen receptor modulator and uses thereof
|
|
US20160024591A1
(en)
|
2013-03-14 |
2016-01-28 |
Wake Forest University Health Sciences |
Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
|
|
JP2016515132A
(ja)
|
2013-03-14 |
2016-05-26 |
ジェネンテック， インコーポレイテッド |
Ｍｅｋ阻害剤化合物のｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び使用方法
|
|
SG10201706210WA
(en)
|
2013-03-15 |
2017-09-28 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
|
UA118846C2
(uk)
|
2013-03-21 |
2019-03-25 |
Новартіс Аг |
Комбінована терапія
|
|
US9314460B1
(en)
|
2013-04-09 |
2016-04-19 |
Stc.Unm |
Method for cancer cell reprogramming
|
|
KR101514877B1
(ko)
|
2013-05-06 |
2015-04-24 |
조선대학교산학협력단 |
ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
|
|
US20170080093A1
(en)
|
2013-10-22 |
2017-03-23 |
Tyme, Inc. |
Tyrosine Derivatives And Compositions Comprising Them
|
|
CA3240745A1
(en)
*
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
AU2014368927B2
(en)
*
|
2013-12-20 |
2018-10-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatments using combinations of CDK and ERK inhibitors
|
|
WO2015150826A1
(en)
|
2014-04-04 |
2015-10-08 |
Astrazeneca Ab |
Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer
|
|
EP3131552B1
(en)
|
2014-04-16 |
2020-07-15 |
Signal Pharmaceuticals, LLC |
Methods for treating cancer using tor kinase inhibitor combination therapy
|
|
ES2686549T3
(es)
|
2014-06-16 |
2018-10-18 |
Worldwide Innovative Network |
Método para seleccionar una triterapia personalizada para el tratamiento del cáncer
|
|
US9446148B2
(en)
|
2014-10-06 |
2016-09-20 |
Mayo Foundation For Medical Education And Research |
Carrier-antibody compositions and methods of making and using the same
|
|
CN107801378A
(zh)
|
2015-05-22 |
2018-03-13 |
普莱希科公司 |
用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904
|
|
US10702527B2
(en)
|
2015-06-12 |
2020-07-07 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
|
AU2016282674B2
(en)
|
2015-06-22 |
2022-01-13 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
WO2017019279A1
(en)
|
2015-07-27 |
2017-02-02 |
Southern Research Institute |
Methods and compositions to treat cancers involving egfr
|
|
US20180243304A1
(en)
|
2015-08-28 |
2018-08-30 |
Novartis Ag |
Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
|
|
WO2017040990A1
(en)
|
2015-09-03 |
2017-03-09 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles and uses thereof
|
|
CA2998472A1
(en)
|
2015-09-15 |
2017-03-23 |
Swedish Health Services |
Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
|
|
WO2017070475A1
(en)
|
2015-10-22 |
2017-04-27 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
|
|
AU2017205478A1
(en)
|
2016-01-07 |
2018-06-28 |
Swadesh K. Das |
A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
|
|
US11311540B2
(en)
|
2016-02-17 |
2022-04-26 |
Acetylon Pharmaceuticals, Inc. |
Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs
|
|
TW201813644A
(zh)
|
2016-09-23 |
2018-04-16 |
江蘇恆瑞醫藥股份有限公司 |
酪胺酸激酶抑制劑在製備治療癌症藥物中的用途
|
|
WO2018127786A1
(en)
|
2017-01-06 |
2018-07-12 |
Oslo Universitetssykehus Hf |
Compositions and methods for determining a treatment course of action
|
|
CN106822905B
(zh)
|
2017-03-08 |
2019-05-17 |
暨南大学 |
含Survivin抑制剂和IRE1抑制剂的药物及用途
|
|
WO2018218633A1
(en)
|
2017-06-02 |
2018-12-06 |
Beijing Percans Oncology Co. Ltd. |
Combination therapies for treating cancers
|
|
US12571049B2
(en)
|
2018-03-21 |
2026-03-10 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
|
|
WO2019195959A1
(en)
|
2018-04-08 |
2019-10-17 |
Cothera Biosciences, Inc. |
Combination therapy for cancers with braf mutation
|
|
WO2020034061A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co., Ltd. |
Biomarkers for cancer therapy
|
|
WO2020097901A1
(en)
|
2018-11-16 |
2020-05-22 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|
|
WO2020036852A1
(en)
|
2018-08-13 |
2020-02-20 |
Beijing Percans Oncology Co. Ltd. |
Biomarkers for cancer therapy
|